Company intelligence / Profile preview

Innocan Pharma Corporation

Ownership: Private
Development stage: Preclinical

Overview

The company has received positive feedback from the FDA following a pre-IND Type B meeting for their LPT-CBD technology. They have conducted pre-clinical trials showing significant pain relief in companion dogs with osteoarthritis. The FDA's Center for Veterinary Medicine has granted a fee waiver and assigned an Investigational New Animal Drug number for their LPT-CBD product[3][5].

Therapeutic areas: RheumatologyNeurology
Modalities: Liposomal drug deliverySmall moleculesCannabidiol (CBD)
Industry: Biotech

Drug pipeline

1 asset

LPT-CBD

Partnerships

Collaboration with Hebrew University in Jerusalem[5]

Beyond the preview

Go deeper on Innocan Pharma Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innocan Pharma Corporation.

Explore the full profile